Fig. 7.

Stable NF-YAx transfectants are tumorigenic and doxorubicin-resistant. a Line graphs demonstrating similar proliferation rates in MTS (left) and ³H-thymidine incorporation assays by stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and  x2 SH-SY5Y-transfectants, displayed as mean (±SD) absorbance at 429 nm for MTS assays and cpm per cell in ³H-thymidine incorporation assays, in three independent assays performed in duplicate. b Micrographs demonstrating similar neuro-sphere growth by stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and  x2-transfectants in neural stem cell assays (bar = 1 mm). c) Micrographs demonstrating similar soft agar spheroid-growth in vitro by stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and  x2-transfectants (bar = 1 mm). d Subcutaneous xenograft tumours formed by stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and  x2-transfectants in NGS mice (bar = 1 cm), plus histogram demonstrating mean (± SD) tumor volumes (mm³) for each group (* = significant). e Micrographs demonstrating the effect of 24 h treatment of stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and NF-YA x2 SH-SY5Y-transfectant with 5 μM doxorubicin (5 μM dox 24 h) compared to controls (Cont 24 h), with mean (±SD) percent death indicated below each cell line (bar = 50 μm) plus Line graphs showing differences in stable pcDNA, NF-YAl, NF-YAs, NF-YAx1 and  x2-stable SH-SY5Y-transfectant sensitivity to 10, 5, 1, 0.1 and 0.01 μM doxorubicin at 0, 6, 24 and 48 h, in AO/EtBr cell death assays, displayed as mean (± SD) percent death in three independent experiments performed in duplicate (* = significant)